InMed’s CEO, Eric A. Adams, joins the 2022 Edison Open House Global Healthcare Conference on January 25th.
In this discussion, Eric talks about the untapped potential of the rare cannabinoid market and how the company is well-positioned to take a lead in this emerging market. He also talks about the recent launch of rare cannabinoid, cannabicitran or CBT, as a raw ingredient for the health and wellness industry, the company’s Phase 2 program of rare cannabinoid cannabinol as a potential treatment for epidermolysis bullosa and the library of new patentable cannabinoid analogs being developed.
With the recent acquisition of BayMedica, InMed’s rare cannabinoid programs now span a broad range of specialties – from cannabinoid manufacturing to pharmaceutical development to commercial sales of rare cannabinoids as raw ingredients for the health and wellness sector. The acquisition has also bolstered the team, adding significant cannabinoid knowledge and expertise in biosynthesis and synthetic biology and chemistry.
